Bolt Biotherapeutics, Inc. (BOLT) stock
BOLTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 11/3030% below fair value
$6.08+0.17 (+2.88%)
Close on Nov 13, 2026Market cap $11.71MP/E –Yield –
Bolt Biotherapeutics total assets
Total assets on the balance sheet at the end of each period.
Bolt Biotherapeutics's total assets was $35.59M at Sep 30, 2026. For fiscal 2025 it was $56.75M, down 43.0% from the year before. The highest annual figure on record is $307.72M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $56.75M | -43.0% |
| FY2024 | Dec 31, 2024 | $99.63M | -37.6% |
| FY2023 | Dec 31, 2023 | $159.78M | -29.9% |
| FY2022 | Dec 31, 2022 | $227.81M | -26.0% |
| FY2021 | Dec 31, 2021 | $307.72M | +561.2% |
| FY2020 | Dec 31, 2020 | $46.54M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $35.59M | -45.3% |
| Q2 FY2026 | Jun 30, 2026 | $40.18M | -46.8% |
| Q1 FY2026 | Mar 31, 2026 | $48.03M | -44.1% |
| Q4 FY2025 | Dec 31, 2025 | $56.75M | -43.0% |
| Q3 FY2025 | Sep 30, 2025 | $65.05M | -40.5% |
| Q2 FY2025 | Jun 30, 2025 | $75.50M | -39.2% |
| Q1 FY2025 | Mar 31, 2025 | $85.86M | -39.9% |
| Q4 FY2024 | Dec 31, 2024 | $99.63M | -37.6% |
| Q3 FY2024 | Sep 30, 2024 | $109.33M | -37.6% |
| Q2 FY2024 | Jun 30, 2024 | $124.18M | -34.9% |
| Q1 FY2024 | Mar 31, 2024 | $142.89M | -30.7% |
| Q4 FY2023 | Dec 31, 2023 | $159.78M | -29.9% |
| Q3 FY2023 | Sep 30, 2023 | $175.36M | -28.6% |
| Q2 FY2023 | Jun 30, 2023 | $190.70M | -26.7% |
| Q1 FY2023 | Mar 31, 2023 | $206.18M | -27.1% |
| Q4 FY2022 | Dec 31, 2022 | $227.81M | -26.0% |
| Q3 FY2022 | Sep 30, 2022 | $245.51M | -26.4% |
| Q2 FY2022 | Jun 30, 2022 | $260.24M | -25.0% |
| Q1 FY2022 | Mar 31, 2022 | $282.79M | -12.9% |
| Q4 FY2021 | Dec 31, 2021 | $307.72M | +561.2% |
| Q3 FY2021 | Sep 30, 2021 | $333.55M | – |
| Q2 FY2021 | Jun 30, 2021 | $347.07M | – |
| Q1 FY2021 | Mar 31, 2021 | $324.64M | – |
| Q4 FY2020 | Dec 31, 2020 | $46.54M | – |
See a number that looks wrong?